Lasagna Angioletta, Cassaniti Irene, Lilleri Daniele, Quaccini Mattia, Ferrari Alessandra, Sacchi Paolo, Bruno Raffaele, Baldanti Fausto, Pedrazzoli Paolo
Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Front Med (Lausanne). 2022 Oct 26;9:1036473. doi: 10.3389/fmed.2022.1036473. eCollection 2022.
Emergency use authorization of drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by regulatory authorities has provided new options to treat high-risk outpatients with mild-to-moderate Coronavirus disease 2019 (COVID-19). We conducted an ambispective cohort study of patients with solid tumors on active treatment to examine the effectiveness of these drugs in preventing the progression to severe COVID-19. Sixty-nine patients with solid tumors (43 women, 26 men; median age 61, range 26-80) reported a laboratory-confirmed diagnosis of SARS-CoV-2 infection. Forty-nine patients received early therapy. Only one patient (14.5%) required hospitalization for COVID-19. As for safety, two patients (5.9%) reported nausea during nirmatrelvir/ritonavir. The majority of treated patients showed a reduced time to negative sample (73 18%, = 0.0011) and shorter symptoms' duration (94 27%; < 0.0001) compared to the patients not treated with the early COVID-19 therapies. Our data suggest that early therapies may reduce the morbidity of COVID-19 in patients with solid tumors.
监管机构对针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的药物的紧急使用授权为治疗轻度至中度2019冠状病毒病（COVID-19）的高危门诊患者提供了新的选择。我们对正在接受积极治疗的实体瘤患者进行了一项双向队列研究，以检查这些药物在预防进展为重症COVID-19方面的有效性。69例实体瘤患者（43例女性，26例男性；中位年龄61岁，范围26 - 80岁）报告经实验室确诊感染SARS-CoV-2。49例患者接受了早期治疗。只有1例患者（14.5%）因COVID-19需要住院治疗。至于安全性，2例患者（5.9%）在服用奈玛特韦/利托那韦期间报告有恶心症状。与未接受早期COVID-19治疗的患者相比，大多数接受治疗的患者样本转阴时间缩短（73 ± 18%，P = 0.0011），症状持续时间缩短（94 ± 27%；P < 0.0001）。我们的数据表明，早期治疗可能降低实体瘤患者中COVID-19的发病率。
